Shares of Aduro Biotech Inc. (NASDAQ:ADRO) shot up 3.2% during trading on Friday . The stock traded as high as $15.70 and last traded at $15.70, with a volume of 185,659 shares trading hands. The stock had previously closed at $15.22.

Several brokerages have recently commented on ADRO. Canaccord Genuity restated a “buy” rating and issued a $30.00 target price on shares of Aduro Biotech in a research note on Friday, August 5th. FBR & Co restated a “buy” rating on shares of Aduro Biotech in a research note on Friday, April 29th. Zacks Investment Research downgraded Aduro Biotech from a “hold” rating to a “sell” rating in a research note on Monday, July 18th. Roth Capital restated a “buy” rating and issued a $22.00 target price on shares of Aduro Biotech in a research note on Monday, July 11th. Finally, Leerink Swann restated a “buy” rating and issued a $48.00 target price on shares of Aduro Biotech in a research note on Thursday, May 5th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $22.00.

The company has a 50-day moving average of $13.46 and a 200-day moving average of $13.24. The stock’s market cap is $1.02 billion.

Aduro Biotech (NASDAQ:ADRO) last issued its quarterly earnings data on Wednesday, August 3rd. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.18) by $0.21. The firm had revenue of $39 million for the quarter, compared to the consensus estimate of $25.24 million. The firm’s revenue for the quarter was up 306.3% compared to the same quarter last year. Equities analysts forecast that Aduro Biotech Inc. will post ($1.15) earnings per share for the current year.

In other news, insider Thomas W. Dubensky sold 25,000 shares of the company’s stock in a transaction dated Thursday, August 11th. The shares were sold at an average price of $15.18, for a total transaction of $379,500.00. Following the completion of the transaction, the insider now directly owns 12,500 shares of the company’s stock, valued at $189,750. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

A hedge fund recently raised its stake in Aduro Biotech stock. Jennison Associates LLC boosted its stake in shares of Aduro Biotech Inc. (NASDAQ:ADRO) by 9.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 855,338 shares of the company’s stock after buying an additional 74,073 shares during the period. Jennison Associates LLC owned approximately 1.35% of Aduro Biotech worth $24,069,000 at the end of the most recent reporting period.

Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.